Solu-Cortef Shortage: What Providers and Prescribers Need to Know in 2026

Hydrocortisone sodium succinate (Solu-Cortef) is a foundational drug in emergency medicine, endocrinology, critical care, and rheumatology. Its recurring supply disruptions — most prominently in 2023 and again in 2025 — have forced providers to develop contingency protocols, substitute regimens, and patient communication strategies. This guide provides a comprehensive clinical overview for prescribers managing Solu-Cortef access challenges in 2026.

Current Supply Status (2026)

As of October 2025, the ASHP confirmed that Pfizer has all Solu-Cortef presentations available, and no active FDA drug shortage is designated heading into 2026. All vial strengths — 100 mg, 250 mg, 500 mg, and 1,000 mg ACT-O-VIAL presentations, as well as the 100 mg plain vial — have been restored to general availability through wholesalers and distributors.

However, localized stocking inconsistencies remain possible, particularly at retail pharmacies supplying home emergency kits for adrenal insufficiency patients. Providers should not assume uniform access across all dispensing channels.

Shortage Chronology: 2023 Through 2025

March 2023: Pfizer announced a supply disruption for Solu-Cortef 100 mg/2 mL ACT-O-VIAL Single Dose Vials (NDC 00009-0011-03 and 00009-0011-04) secondary to quality issues and demand surge. All inventory restricted to direct-order allocation to institutions with purchase history. FDA notified. Pfizer Supply Continuity Team activated.

May 2023: FDA issued emergency expiration date extension for 32 lots — extended five months beyond the labeled 36-month shelf life. Recovery initially projected for June 2023, later extended to December 2023.

April 2025: Pfizer notified of a second short-term interruption in the 25-pack presentation (NDC 00009-0011-04) due to increased demand and a manufacturing delay that had been resolved. Recovery projected Q3 2025. FDA notified. 1-vial presentation (NDC 00009-0011-03), 250 mg, 500 mg, and 1,000 mg presentations maintained at 100-125% of baseline allocation.

October 2025: ASHP database updated: all presentations available; shortage formally resolved.

Therapeutic Alternatives: Clinical Considerations

When Solu-Cortef is unavailable, the choice of alternative depends critically on the underlying clinical indication. The key distinction is whether mineralocorticoid activity is required:

Indications Where Mineralocorticoid Activity Is Critical

For patients with primary adrenal insufficiency (Addison's disease) or congenital adrenal hyperplasia (CAH), hydrocortisone's mineralocorticoid activity is essential during stress-dosing and adrenal crisis management. If Solu-Cortef or its generic (A-Hydrocort) is unavailable:

Dexamethasone sodium phosphate or methylprednisolone sodium succinate may serve as glucocorticoid substitutes but require supplemental fludrocortisone to address mineralocorticoid deficiency in primary adrenal failure

Dose conversion: 100 mg hydrocortisone ≈ 20 mg methylprednisolone ≈ 4 mg dexamethasone (glucocorticoid equivalence only — no mineralocorticoid effect)

Hydrocortisone's biological half-life is 8–12 hours; dexamethasone's is 36–72 hours — dose frequency must be adjusted accordingly

Indications Where Mineralocorticoid Activity Is Not Required

For severe allergic reactions, asthma exacerbations, autoimmune flares, and other inflammatory indications in patients with intact adrenal function, dexamethasone or methylprednisolone sodium succinate (Solu-Medrol) are clinically appropriate substitutes. Solu-Medrol is preferred over Solu-Cortef for extended high-dose therapy (beyond 48-72 hours) due to lower sodium retention.

Generic Substitution: A-Hydrocort

A-Hydrocort (hydrocortisone sodium succinate injection, generic) is the simplest and most appropriate first-line substitute for Solu-Cortef. It is therapeutically equivalent, available in the same strengths, and typically priced lower. Prescribers should note that if brand and generic share the same manufacturing source, both may be simultaneously unavailable during a Pfizer-specific disruption — in that scenario, the alternatives above become necessary.

Protocols for Adrenal Insufficiency Patients: Home Emergency Kit Access

Patients with adrenal insufficiency presenting for routine refills of home emergency kits require special attention during shortage periods. Recommended provider actions:

Proactive prescribing: Prescribe refills well before expiration. Consider prescribing backup kits for high-risk patients.

Hospital pharmacy routing: Route prescriptions through hospital pharmacies with direct Pfizer purchasing relationships during retail-level shortages.

503B compounding pharmacies: FDA-registered 503B compounders can prepare hydrocortisone sodium succinate injection as a shortage alternative.

Patient education: Ensure all adrenal insufficiency patients have updated sick-day rules, current emergency kit instructions, and know to go directly to an ER if they cannot obtain Solu-Cortef during a crisis.

Resources for Providers

ASHP Drug Shortage Database: ashp.org/drug-shortages — real-time shortage status and clinical guidance

Pfizer Supply Continuity Team: 1-844-646-4398, option 1 (Customer) then option 3 (Supply Continuity), M-F 7 a.m.-5 p.m. CT

Pfizer Hospital Availability Report: PfizerHospitalUS.com — updated frequently with product-level availability data

medfinder also offers a provider-facing service to help your patients locate in-stock pharmacies near them. Visit medfinder for providers to learn more.

See also: How to help your patients find Solu-Cortef in stock — a provider's guide.